Have a personal or library account? Click to login
Mortality after radial-only balloon aortic valvuloplasty: a long-term follow-up and a bridge-to-TAVI analysis Cover

Mortality after radial-only balloon aortic valvuloplasty: a long-term follow-up and a bridge-to-TAVI analysis

Open Access
|Aug 2023

Figures & Tables

Figure 1

Proposed algorithm for transradial BAV, regarding sheath and balloon size selection. Steps: (1) Measure the LOVT size by transthoracic ultrasound; (2) Select balloon type (use low profile 7-8F compatible balloon); (3) Select balloon size (0.8 balloon/LVOT ratio); (4) Perform vascular ultrasound (radial and ulnar artery size, calcification). Abbreviation: BAV, balloon aortic valvuloplasty; LVOT, left ventricular outflow tract.
Proposed algorithm for transradial BAV, regarding sheath and balloon size selection. Steps: (1) Measure the LOVT size by transthoracic ultrasound; (2) Select balloon type (use low profile 7-8F compatible balloon); (3) Select balloon size (0.8 balloon/LVOT ratio); (4) Perform vascular ultrasound (radial and ulnar artery size, calcification). Abbreviation: BAV, balloon aortic valvuloplasty; LVOT, left ventricular outflow tract.

Figure 2

Competing risk analysis curves.
Competing risk analysis curves.

Effect of BAV_ CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LV, left ventricle; EDD, end diastolic diameter; ESD, end systolic diameter; AI, aortic insufficiency

 Before BAVAfter BAVP-value
Symptoms scores
Angina class (CCS)  0.025
016 (53.3%)23 (76.7%) 
12 (6.67%)5 (16.7%) 
25 (16.7%)2 (6.67%) 
33 (10.0%)0 (0.0%) 
44 (13.3%)0 (0.0%) 
NYHA class  <0.001
10 (0.0%)8 (26.7%) 
20 (0.0%)18 (60.0%) 
315 (50.0%)2 (6.67%) 
415 (50.0%)2 (6.67%) 
Catheterization
Peak-to-peak gradient across aortic valve, mmHg94.6±31.940.0±15.6<0.001
Echocardiography
LVEF, %47.9±17.650.2±13.80.593
LV EDD, mm52.0 (45.2-59.0)48.0 (44.5-58.0)0.585
LV ESD, mm36.7±9.6037.2±8.210.773
Aortic valve peak gradient, mmHg87.1±8.863.3±29.30.004
Aortic valve mean gradient, mmHg56.0±20.236.7±14.00.092
AI grade  0.515
014 (46.6%)3 (10%) 
110 (33.3%)14 (46.6%) 
25 (16.6%)12 (40%) 
31 (3.33%)1 (3.33%) 

Procedural characteristics

VariableValue
Sheath #1 size (French) 
5, n (%)1 (3.33%)
6, n (%)1 (3.33%)
7, n (%)13 (43.3%)
8, n (%)12 (40.0%)
9, n (%)1 (3.33%)
10, n (%)2 (6.67%)
Sheath #2 size (French) 
5, n (%)3 (10.0%)
6, n (%)24 (80.0%)
7, n (%)2 (6.67%)
8, n (%)1 (3.33%)
Balloon size 
14x20, n (%)1 (3.33%)
14x40, n (%)2 (6.67%)
16x20, n (%)1 (3.33%)
16x40, n (%)12 (40.0%)
18x40, n (%)13 (43.3%)
2x12x40, n (%)1 (3.33%)
Contrast volume, mL82.7 (39.8)
Procedure time, min48.2 (12.5)

Patient characteristics_ TAVI, transcatheter aortic valve implantation; BMI, body mass index; CKD, chronic kidney disease; DM, diabetes mellitus; AHT, arterial hypertension; MI, myocardial infarction; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; balloon aortic valvuloplasty, BAV_

 All patients (N=30)BAV only (N=14)BAV + TAVI (N=16)P-value
Length of follow-up, months22.8 (21.3-24.3)21.9 (10.4-24.2)23.0 (22.1-24.3)0.253
Time to TAVI, months  3.33 (2.49-4.38)NA
Age, years78.3±7.1479.4±5.6277.4±8.310.443
Male, n (%)12 (40.0%)5 (35.7%)7 (43.8%)0.940
BMI, kg/m226.7 (23.2-29.4)26.6 (24.0-29.3)26.7 (22.8-29.3)0.835
CKD, n (%)15 (50.0%)10 (71.4%)5 (31.2%)0.067
DM, n (%)14 (46.7%)7 (50.0%)7 (43.8%)1.000
AHT, n (%)27 (90.0%)12 (85.7%)15 (93.8%)0.586
Smoking, n (%)2 (6.67%)1 (7.14%)1 (6.25%)1.000
Family history of cardiovascular disease, n (%)4 (13.3%)3 (21.4%)1 (6.25%)0.315
Dyslipidemia, n (%)17 (56.7%)8 (57.1%)9 (56.2%)1.000
Previous MI, n (%)8 (26.7%)5 (35.7%)3 (18.8%)0.417
Previous CABG, n (%)0 (0.0%)0 (0.0%)0 (0.0%)1.000
COPD, n (%)2 (6.67%)2 (14.3%)0 (0.00%)0.209
Atrial fibrillation, n (%)13 (43.3%)7 (50.0%)6 (37.5%)0.749
CVA, n (%)2 (6.67%)1 (7.14%)1 (6.25%)1.000
Permanent pacemaker, n (%)1 (3.33%)1 (7.14%)0 (0.00%)0.467
Peripheral artery disease, n (%)14 (46.7%)7 (50.0%)7 (43.8%)1.000
Initial BAV indication   0.782
Severe aortic stenosis21 (70.0%)11 (78.6%)10 (62.5%) 
Severe aortic stenosis + acute heart failure7 (23.3%)3 (21.4%)4 (25.0%) 
Severe aortic stenosis + cardiogenic shock2 (6.66%)0 (0.00%)2 (12.5%) 
Repeat BAV1 (3.33%)1 (7.14%)0 (0.00%)0.467

Estimates accompanying the cumulative incidence analysis (Figure 2)

Time (months)Number at riskTAVI, %Death, %Alive without TAVI, %
1300.0 (0.0-0.0)0.0 (0.0-0.0)100 (100-100)
22610.0 (2.5-23.9)3.3 (0.2-14.8)83.7 (75.3-99.7)
32220.0 (7.9-36.0)6.7 (1.1-19.4)73.3 (59.1-91.0)
41930.0 (14.7-46.9)6.7 (1.1-19.4)63.3 (48.2-83.2)
51640.0 (22.4-57.0)6.7 (1.1-19.4)53.3 (38.2-74.5)
101150.0 (30.8-66.5)13.3 (4.0-28.3)36.7 (22.9-58.7)
151050.0 (30.8-66.5)16.7 (5.8-32.3)33.3 (20.1-55.3)
20950.0 (30.8-66.5)20.0 (7.8-36.2)30.0 (17.4-51.8)
25350.0 (30.8-66.5)20.0 (7.8-36.2)30.0 (17.4-51.8)
DOI: https://doi.org/10.2478/rjc-2023-0014 | Journal eISSN: 2734-6382 | Journal ISSN: 1220-658X
Language: English
Page range: 93 - 98
Published on: Aug 1, 2023
Published by: Romanian Society of Cardiology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2023 Alexandru Achim, Jef Van den Eynde, Tamás Szűcsborus, Viktor Sasi, Ferenc Nagy, Zoltán Jambrik, Attila Nemes, Albert Varga, Zoltán Ruzsa, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.